炎症性肠病中的胆汁酸：从病理生理学到治疗

Bai Samantha H, Chandnani Arun, Cao Siyan

Division of Gastroenterology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.

Biomedicines. 2024 Dec 20;12(12):2910. doi: 10.3390/biomedicines12122910.

Inflammatory bowel disease (IBD) is a chronic condition that affects about 7 million people worldwide, and new therapies are needed. Understanding the complex roles that bile acids (BAs) play in IBD may lead to the development of novel IBD treatments independent of direct immunosuppression. This review discusses the latest discoveries in the roles BAs play in IBD pathogenesis and explores how these discoveries offer promising new therapeutic targets to treat IBD and improve patient outcomes. Several therapies discussed include specific BA receptor (BAR) agonists, dietary therapies, supplements, probiotics, and mesenchymal stem cell therapies that have all been shown to decrease IBD disease activity.

炎症性肠病（IBD）是一种慢性病，全球约有700万人受其影响，因此需要新的治疗方法。了解胆汁酸（BAs）在IBD中所起的复杂作用，可能会促成独立于直接免疫抑制的新型IBD治疗方法的开发。本综述讨论了胆汁酸在IBD发病机制中作用的最新发现，并探讨了这些发现如何为治疗IBD和改善患者预后提供有前景的新治疗靶点。所讨论的几种治疗方法包括特定的胆汁酸受体（BAR）激动剂、饮食疗法、补充剂、益生菌和间充质干细胞疗法，这些疗法均已显示可降低IBD疾病活动度。